Oregon Health & Science University wins breakthrough stem-cell patent; ethics of cloning debated
By Nick Budnick,
The Oregonian
| 11. 02. 2011
Oregon Health & Science University's patent on a procedure to clone stem cells caps off a decade of work for Shoukhrat Mitalipov and his research team at OHSU's primate center.
The 2007 discovery, ranked by TIME Magazine one of the top two research advances of the year, now can be commercialized. Over the long-term, observers say, it could lead to the genetic engineering of human beings. But OHSU's announcement yesterday focused on short-term health gains.
“We believe our procedure has several advantages over other methods in developing new treatments for diseases such as Parkinson’s, multiple sclerosis, cardiac disease and spinal cord injuries,” said Mitalipov, an associate scientist in the Division of Reproductive Sciences. “For instance, because we transform a person’s own cells, there are no issues of rejection when the stem cells are transplanted back into a patient.”
What follows are links tracking the patent announcement, the earlier news and the resulting ethical debate over human cloning.
OHSU's Shoukhrat Mitalipov, Ph.D., discusses newly developed gene therapy method (OHSU via Youtube.com)
Scientists use monkey clones to extract stem cells (New York...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...